1997
DOI: 10.1002/chin.199712235
|View full text |Cite
|
Sign up to set email alerts
|

ChemInform Abstract: Unusual Isoxazoline Formation by Intramolecular Cyclization of (9E)‐ Erythromycin A Oxime.

Abstract: ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2016
2016
2016
2016

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 1 publication
0
1
0
Order By: Relevance
“…This approach resulted in various new chemical entities [ 43 , 44 , 45 ]. The most important erythromycin derivative from this group of new derivatives was erythromycin A oxime, prepared from erythromycin A and hydroxylamine hydrochloride in the presence of a weak base and buffer ( Figure 2 ) [ 46 , 47 , 48 ]. The same was identified by chemists at PLIVA (the largest pharmaceutical company in Croatia and one of the leading companies in Southeast Europe and, today, a member of the Teva Group) and the work continued for the further synthesis of new, more active compounds, such as roxithromycin, dirithromycin, and clarithromycin.…”
Section: From Erythromycin To Azithromycinmentioning
confidence: 99%
“…This approach resulted in various new chemical entities [ 43 , 44 , 45 ]. The most important erythromycin derivative from this group of new derivatives was erythromycin A oxime, prepared from erythromycin A and hydroxylamine hydrochloride in the presence of a weak base and buffer ( Figure 2 ) [ 46 , 47 , 48 ]. The same was identified by chemists at PLIVA (the largest pharmaceutical company in Croatia and one of the leading companies in Southeast Europe and, today, a member of the Teva Group) and the work continued for the further synthesis of new, more active compounds, such as roxithromycin, dirithromycin, and clarithromycin.…”
Section: From Erythromycin To Azithromycinmentioning
confidence: 99%